CNR2 and Parkinson disease: As the CB2 agonist GW842166x exhibited good bioavailability and was found to be safe and well-tolerated by patients without serious adverse effects [36], we employed a neurotoxic model of PD through unilateral injection of 6-hydroxydopamine (6-OHDA) into the striatum and examined the neuroprotective effects of treatment with the CB2 agonist GW842166x [37].